Manufacturing: Page 10


  • Thermo Fisher rakes in $1.3B in coronavirus-related revenue

    The second quarter saw the company's diagnostic and healthcare end market sales jump more than 70% due to soaring demand for COVID-19 testing.

    By Nick Paul Taylor • July 22, 2020
  • Ventec ventilator being worked on at GM's retooled parts plant in Kokomo, Indiana.
    Image attribution tooltip
    Courtesy of https://ventecgm.com/
    Image attribution tooltip

    An insider's look at how GM, Ventec ramped up ventilator production amid COVID-19

    The weight of the Defense Production Act helped open doors, said the CEO of the engineering firm contracted to test each of the 30,000 devices expected under the agreement.

    By Greg Slabodkin • July 13, 2020
  • Image attribution tooltip
    Novartis
    Image attribution tooltip

    Civica enlists Novartis to produce generic injectable drugs

    Founded by hospital systems to address drug shortages, the nonprofit group has now struck several partnerships to expand its network of suppliers.

    By Kristin Jensen • July 9, 2020
  • Image attribution tooltip
    Regeneron
    Image attribution tooltip

    US buys up early supply of Regeneron's COVID-19 antibody cocktail

    A $450 million grant will help Regeneron scale up manufacturing of its drug, which is among the front-running antibody therapies for COVID-19.

    By July 7, 2020
  • Novavax COVID-19 candidate vaccine NVX-CoV2373 administered to first patients in Phase I Clinical Trial
    Image attribution tooltip
    Courtesy of Novavax, Australian Broadcasting Corporation
    Image attribution tooltip

    Novavax gets $1.6B in US funding for coronavirus vaccine

    The funding will secure 100 million doses of Novavax's experimental shot, which is set to begin late-stage testing this fall.

    By Ned Pagliarulo • July 7, 2020
  • Image attribution tooltip
    Janssen
    Image attribution tooltip

    J&J, with new deal, plans for long-term manufacture of coronavirus vaccine

    A five-year agreement with Maryland's Emergent Biosolutions will provide for large-scale production of J&J's candidate, set to begin testing in July.

    By Ned Pagliarulo • July 6, 2020
  • Image attribution tooltip
    Jacob Bell
    Image attribution tooltip

    Novartis cancer drug unit to build Indianapolis factory

    Advanced Accelerator Applications, a subsidiary of the Swiss pharma, will build a new site to produce targeted radioligand therapies like Lutathera.

    By Kristin Jensen • July 2, 2020
  • A volunteer in a clinical trial is dosed with BNT162, an experimental coronavirus vaccine developed by Pfizer and BioNTech
    Image attribution tooltip
    Permission granted by BioNTech SE
    Image attribution tooltip

    WHO lays out ambitious plan to deliver 2 billion coronavirus vaccine doses

    More than $18 billion will be needed for the WHO's plan, which would secure and allocate vaccine supplies for high-risk groups and lower-income countries.

    By Ned Pagliarulo • June 26, 2020
  • Image attribution tooltip
    Moderna
    Image attribution tooltip

    Moderna adds Catalent as vaccine manufacturing partner

    Catalent will help with some of the final manufacturing steps for the biotech's experimental coronavirus vaccine, set to begin late-stage testing next month.

    By Kristin Jensen • June 25, 2020
  • A transmission electron microscope image of SARS-CoV-2, isolated from a patient in the U.S.
    Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2020). "Novel coronavirus SARS-CoV-2" [Microscope image]. Retrieved from https://www.flickr.com/photos/nihgov/49535193876/in/album-72157713108522106/.
    Image attribution tooltip

    Inovio gets U.S. government backing for vaccine delivery device

    The contract from the U.S. Department of Defense will help Inovio scale up production of its coronavirus vaccine, which, unlike many rivals, relies on an electroporation device.  

    By Kristin Jensen • June 24, 2020
  • Lonza building in Basel, Switzerland
    Image attribution tooltip
    Courtesy of Lonza Ltd.
    Image attribution tooltip
    Deep Dive

    Vaccines can end the coronavirus pandemic. Will every country get them?

    Scientists around the world are racing to develop a coronavirus vaccine. But the factories slated to make the leading candidates are concentrated in a handful of countries, raising concerns about global access.

    By June 23, 2020
  • President Trump Delivers an Update on Vaccine Development on May 15, 2020
    Image attribution tooltip
    Craighead, Shealah. (2020). "President Trump Delivers an Update on Vaccine Development" [Photograph]. Retrieved from Flickr.
    Image attribution tooltip

    'Warp Speed' plan for coronavirus vaccines comes into focus

    Developers backed by the project will get preferential access to manufacturing and distribution capacity secured by the U.S. government.

    By Ned Pagliarulo • June 17, 2020
  • A vial of BNT162, an experimental coronavirus vaccine being developed by BioNTech and Pfizer
    Image attribution tooltip
    Permission granted by BioNTech SE
    Image attribution tooltip

    EU proposes countries band together to buy coronavirus vaccines

    The European Union plans to spend billions from an emergency fund to make advanced purchases of coronavirus vaccines for its member states. 

    By Kristin Jensen • June 17, 2020
  • Image attribution tooltip
    Sanofi Pasteur
    Image attribution tooltip

    Sanofi's latest investment signals long-term focus on vaccines

    The new coronavirus has brought a renewed interest in vaccines. Now, Sanofi plans to spend hundreds of millions of dollars preparing for future pandemics.

    By June 16, 2020
  • This transmission electron microscope image shows SARS-CoV-2, the virus that causes COVID-19, isolated from a patient in the U.S.
    Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from https://www.flickr.com/photos/nihgov/49565892277/in/album-72157713108522106/.
    Image attribution tooltip

    AstraZeneca signs new supply deals as coronavirus vaccine data nears

    The drugmaker agreed to provide 400 million doses to four European countries as part of preparations to supply the world with the coronavirus vaccine it licensed from the University of Oxford.

    By June 15, 2020
  • FujiFilm 2,000-litre mammalian cell culture tank
    Image attribution tooltip
    Courtesy of FujiFilm
    Image attribution tooltip

    Fujifilm to invest nearly $1B in Denmark biologics plant

    The Japanese contract manufacturer will double capacity at a biologics plant formerly owned by Biogen.

    By Kristin Jensen • June 10, 2020
  • UPS expands healthcare business, shifting focus to vaccines

    The coronavirus pandemic has forced the carrier to adjust and focus more heavily on the shipping and distribution of potential vaccines and treatments.

    By Matt Leonard • June 10, 2020
  • Image attribution tooltip
    Corning Inc.
    Image attribution tooltip

    US invests in drug vials to support coronavirus vaccine push

    Through BARDA, the U.S. government will spend nearly $350 million to help two vial manufacturers dramatically scale up production.

    By Ned Pagliarulo • June 9, 2020
  • AstraZeneca reaches deals with health charities to supply coronavirus vaccine worldwide

    A separate agreement with India's Serum Institute aims to provide 1 billion doses of the experimental vaccine to low- and middle-income countries.

    By June 4, 2020
  • Novavax COVID-19 candidate vaccine NVX-CoV2373 administered to first patients in Phase I Clinical Trial
    Image attribution tooltip
    Courtesy of Novavax, Australian Broadcasting Corporation
    Image attribution tooltip

    Novavax taps AGC Biologics to aid in production of COVID-19 vaccine

    Like its larger rivals, the Maryland company is trying to add manufacturing capacity for its experimental coronavirus vaccine as quickly as possible. 

    By Kristin Jensen • June 4, 2020
  • US government promises Maryland drug manufacturer $628M to make coronavirus vaccines

    The cash will secure manufacturing capacity at three Emergent sites for coronavirus vaccine developers, part of a sweeping government-led effort to make a protective treatment available as soon as possible.

    By Ned Pagliarulo • June 2, 2020
  • A vial of BNT162, an experimental coronavirus vaccine being developed by BioNTech and Pfizer
    Image attribution tooltip
    Permission granted by BioNTech SE
    Image attribution tooltip

    Facing vial shortage, pharmas explore workarounds for coronavirus vaccines

    "There's not enough vials in the world," said AstraZeneca's CEO on Thursday. Procuring enough to hold the billions of vaccine doses needed is yet another headache for coronavirus drugmakers to solve.

    By Ned Pagliarulo • May 28, 2020
  • The FDA logo on a glass pane at the agency's campus in Silver Spring, Maryland.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    Contaminated diabetes drugs raise red flag for FDA oversight

    The Food and Drug Administration is reaching out to drug manufacturers after finding some metformin pills were contaminated with the carcinogen NDMA.

    By Updated May 29, 2020
  • An electron microscope image of SARS-CoV-2, isolated from a patient in the U.S.
    Image attribution tooltip
    National Institute of Allergy and Infectious Disease. (2020). "Novel Coronavirus SARS-CoV-2" [Microscope image]. Retrieved from https://www.flickr.com/photos/nihgov/49565158853/.
    Image attribution tooltip

    Novartis teams with Mass. Eye & Ear to join coronavirus vaccine chase

    The Swiss pharma has become the latest large drugmaker to enter the worldwide race to develop a vaccine for COVID-19, tapping a project developed by gene therapy experts at the Massachusetts Eye and Ear Hospital.

    By May 28, 2020
  • Novavax COVID-19 candidate vaccine NVX-CoV2373 administered to first patients in Phase I Clinical Trial
    Image attribution tooltip
    Courtesy of Novavax, Australian Broadcasting Corporation
    Image attribution tooltip

    Novavax buys more manufacturing capacity as first COVID-19 vaccine test begins

    The Maryland biopharma has acquired a Czech vaccine developer for $167 million, gaining a facility in Europe that will boost its COVID-19 vaccine production capabilities.   

    By Kristin Jensen • May 28, 2020